Dataset from A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/00006701
下载链接
链接失效反馈官方服务：
资源简介：
The study is designed to evaluate the efficacy and safety of SHP465 in the treatment of ADHD
in children and adolescents (aged 6-17 years). The primary objective of this study is to
evaluate the efficacy of SHP465 administered as a daily morning dose compared to placebo in
the treatment of children and adolescents (6-17 years of age inclusive) diagnosed with ADHD.
创建时间：
2026-03-25
